Need a Note Card?

Don’t look any further. Imagine Note Cards are correspondence cards and are a fabulous addition to your writing desk at home. These cards are perfect for writing a thank you note after a party, or after someone has sent you a gift.

Every year Penny People Designs works with a charity or organizaiton and creates a unique card where 50% of the proceeds from the sale of a card are donated to the charity. Imagine a Cure for Leukemia has been chosen this year by Penny People Designs to be their charity card for 2009. The Cards are $1.50 each and can be customized.
Imagine A Cure for Leukemia is dedicated to expanding the search for a cure with a greater sense of urgency. We are a not-for-profit organization. We raise funds through local community activities and the generosity of individuals and companies in the area. We fund projects where medical breakthroughs have already been achieved and where additional research is needed to turn them into better treatments for people. For more information please visit www.imagineacureforleukemia.com

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap